trelagliptin
Small moleculeexperimental
Trelagliptin is a pharmaceutical drug used for the treatment of type 2 diabetes .Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan and India for the treatment of type 2 diabetes mellitus. Zuventus Healthcare introduced Trelagliptin in India (2025) under the brand name Trelaglip®. — Wikipedia
Clinical trial activity
18 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
9
Phase 3
7
Phase 4
4
Earliest trial started Mar 1, 2007 (NCT00760344)
Timeline
Indications
Approved for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O- Mol. weight
- 357.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1650443 ↗
- WikipediaTrelagliptin ↗
- ChEMBLCHEMBL2105754 ↗
Also known as
- syr111472
- syr-111472 succinate
- syr-111472 succinate
- syr-472
- syr-472
- syr-472
- syr-472
- syr-472
- trelagliptin
- trelagliptin
- trelagliptin
- trelagliptin
- trelagliptin
- trelagliptin
- trelagliptin
- trelagliptin succinate
- trelagliptin succinate
- trelagliptin succinate
- trelagliptin succinate
- zafatek
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07073768 | Phase 3 | Jul 1, 2025 | Khyber Medical University Peshawar, Khyber Medical University Peshawer |
| NCT06889909 | N/A | Dec 15, 2024 | Post-Graduate Medical Institute, Lahore |
| NCT06913101 | N/A | Nov 15, 2024 | PNS Hafeez - Naval Hospital |
| NCT04365907 | N/A | Mar 11, 2020 | British University In Egypt |
| NCT04374864 | Phase 4 | Mar 1, 2020 | Ain Shams University, British University In Egypt |
| NCT03940183 | Phase 3 | Aug 31, 2019 | Shijiazhuang Pharma Group (CSPC) |
| NCT03362398 | N/A | Nov 20, 2017 | British University In Egypt |
| NCT03231709 | Phase 4 | Aug 16, 2017 | Takeda |
| NCT03014479 | Phase 4 | Jan 12, 2017 | Takeda |
| NCT02771093 | Phase 4 | Jun 1, 2016 | Takeda |
| NCT02512068 | Phase 3 | Jul 8, 2015 | Takeda |
| NCT02372097 | Phase 1 | Mar 1, 2015 | Takeda |
| NCT02324569 | Phase 3 | Dec 1, 2014 | Takeda |
| NCT01751360 | Phase 3 | Apr 1, 2013 | Takeda |
| NCT01632007 | Phase 3 | May 1, 2012 | Takeda |
| NCT01431807 | Phase 3 | Sep 1, 2011 | Takeda |
| NCT00653185 | Phase 2 | May 1, 2007 | Takeda |
| NCT00760344 | Phase 2 | Mar 1, 2007 | Takeda |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 11 | 11 | 4 | 2007 |
| British University In Egypt | Academic/Hospital | 3 | 3 | 2 | 2017 |
| Ain Shams University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Khyber Medical University Peshawar | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Khyber Medical University Peshawer | Academic/Hospital | 1 | 0 | 1 | 2025 |
| PNS Hafeez - Naval Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Post-Graduate Medical Institute, Lahore | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 1 | 1 | 2019 |
8 organizations
Page 1 / 1